Treatment of asthma with nebulized lidocaine: A randomized, placebo-controlled study

Loren W. Hunt, Evangelo Frigas, Joseph H. Butterfield, Hirohito Kita, Judith Blomgren, Sandra L. Dunnette, Kenneth P. Offord, Gerald J. Gleich

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background: In 2 prior uncontrolled studies, nebulized lidocaine reduced oral glucocorticoid use in patients with severe glucocorticoid-dependent asthma. Objective: We tested the safety and efficacy of nebulized lidocalne in a randomized, placebo-controlled study in patients with mild-to-moderate asthma. Methods: We recruited 50 subjects (25 receiving lidocaine and 25 receiving placebo); all had a prebronchodilator FEV 1 of 64% to 125% of predicted normal value and were treated with daily inhaled glucocorticoids (but not systemic glucocorticoids) and bronchodilators for at least 2 months. Before treatment, subjects monitored their symptoms and peak flow values and maintained their medications for 2 weeks. At initiation, subjects inhaled either nebulized placebo (saline) or lidocaine (4%, 100 mg) 4 times daily. All subjects were instructed to reduce their inhaled glucocorticoid dosage by one half each week for 3 weeks and to discontinue glucocorticoid treatment at week 4. The subjects continued the nebulized lidocaine or placebo for a total of 8 weeks, monitored their symptoms, and used bronchodilators to control symptoms. Results: Indicators of asthma severity showed benefit for the lidocaine-treated group: changes in FEV 1 (P ≤ .001), nighttime awakenings (P ≤ .02), symptoms (P ≤ .010), bronchodilator use (P ≤ .010), and blood eosinophil counts (P ≤ .020). Subjects in both groups reduced use of inhaled glucocorticoids comparably. Subjects receiving nebulized placebo showed increases in their symptom scores, bronchodilator use (P ≤ .05 for both), and blood eosinophil counts (P ≤ .01) and decreases in FEV 1 (P ≤ .001). Conclusion: Nebulized lidocaine provided effective and safe therapy in subjects with mild-to-moderate asthma.

Original languageEnglish (US)
Pages (from-to)853-859
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume113
Issue number5
DOIs
StatePublished - May 2004

Fingerprint

Lidocaine
Glucocorticoids
Asthma
Placebos
Bronchodilator Agents
Eosinophils
Therapeutics
Reference Values
Safety

Keywords

  • Asthma
  • Eosinophils
  • Glucocorticoids
  • Lidocaine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Hunt, L. W., Frigas, E., Butterfield, J. H., Kita, H., Blomgren, J., Dunnette, S. L., ... Gleich, G. J. (2004). Treatment of asthma with nebulized lidocaine: A randomized, placebo-controlled study. Journal of Allergy and Clinical Immunology, 113(5), 853-859. https://doi.org/10.1016/j.jaci.2004.02.039

Treatment of asthma with nebulized lidocaine : A randomized, placebo-controlled study. / Hunt, Loren W.; Frigas, Evangelo; Butterfield, Joseph H.; Kita, Hirohito; Blomgren, Judith; Dunnette, Sandra L.; Offord, Kenneth P.; Gleich, Gerald J.

In: Journal of Allergy and Clinical Immunology, Vol. 113, No. 5, 05.2004, p. 853-859.

Research output: Contribution to journalArticle

Hunt, LW, Frigas, E, Butterfield, JH, Kita, H, Blomgren, J, Dunnette, SL, Offord, KP & Gleich, GJ 2004, 'Treatment of asthma with nebulized lidocaine: A randomized, placebo-controlled study', Journal of Allergy and Clinical Immunology, vol. 113, no. 5, pp. 853-859. https://doi.org/10.1016/j.jaci.2004.02.039
Hunt, Loren W. ; Frigas, Evangelo ; Butterfield, Joseph H. ; Kita, Hirohito ; Blomgren, Judith ; Dunnette, Sandra L. ; Offord, Kenneth P. ; Gleich, Gerald J. / Treatment of asthma with nebulized lidocaine : A randomized, placebo-controlled study. In: Journal of Allergy and Clinical Immunology. 2004 ; Vol. 113, No. 5. pp. 853-859.
@article{64e453faf1314671ad6d7779fcc9c2df,
title = "Treatment of asthma with nebulized lidocaine: A randomized, placebo-controlled study",
abstract = "Background: In 2 prior uncontrolled studies, nebulized lidocaine reduced oral glucocorticoid use in patients with severe glucocorticoid-dependent asthma. Objective: We tested the safety and efficacy of nebulized lidocalne in a randomized, placebo-controlled study in patients with mild-to-moderate asthma. Methods: We recruited 50 subjects (25 receiving lidocaine and 25 receiving placebo); all had a prebronchodilator FEV 1 of 64{\%} to 125{\%} of predicted normal value and were treated with daily inhaled glucocorticoids (but not systemic glucocorticoids) and bronchodilators for at least 2 months. Before treatment, subjects monitored their symptoms and peak flow values and maintained their medications for 2 weeks. At initiation, subjects inhaled either nebulized placebo (saline) or lidocaine (4{\%}, 100 mg) 4 times daily. All subjects were instructed to reduce their inhaled glucocorticoid dosage by one half each week for 3 weeks and to discontinue glucocorticoid treatment at week 4. The subjects continued the nebulized lidocaine or placebo for a total of 8 weeks, monitored their symptoms, and used bronchodilators to control symptoms. Results: Indicators of asthma severity showed benefit for the lidocaine-treated group: changes in FEV 1 (P ≤ .001), nighttime awakenings (P ≤ .02), symptoms (P ≤ .010), bronchodilator use (P ≤ .010), and blood eosinophil counts (P ≤ .020). Subjects in both groups reduced use of inhaled glucocorticoids comparably. Subjects receiving nebulized placebo showed increases in their symptom scores, bronchodilator use (P ≤ .05 for both), and blood eosinophil counts (P ≤ .01) and decreases in FEV 1 (P ≤ .001). Conclusion: Nebulized lidocaine provided effective and safe therapy in subjects with mild-to-moderate asthma.",
keywords = "Asthma, Eosinophils, Glucocorticoids, Lidocaine",
author = "Hunt, {Loren W.} and Evangelo Frigas and Butterfield, {Joseph H.} and Hirohito Kita and Judith Blomgren and Dunnette, {Sandra L.} and Offord, {Kenneth P.} and Gleich, {Gerald J.}",
year = "2004",
month = "5",
doi = "10.1016/j.jaci.2004.02.039",
language = "English (US)",
volume = "113",
pages = "853--859",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Treatment of asthma with nebulized lidocaine

T2 - A randomized, placebo-controlled study

AU - Hunt, Loren W.

AU - Frigas, Evangelo

AU - Butterfield, Joseph H.

AU - Kita, Hirohito

AU - Blomgren, Judith

AU - Dunnette, Sandra L.

AU - Offord, Kenneth P.

AU - Gleich, Gerald J.

PY - 2004/5

Y1 - 2004/5

N2 - Background: In 2 prior uncontrolled studies, nebulized lidocaine reduced oral glucocorticoid use in patients with severe glucocorticoid-dependent asthma. Objective: We tested the safety and efficacy of nebulized lidocalne in a randomized, placebo-controlled study in patients with mild-to-moderate asthma. Methods: We recruited 50 subjects (25 receiving lidocaine and 25 receiving placebo); all had a prebronchodilator FEV 1 of 64% to 125% of predicted normal value and were treated with daily inhaled glucocorticoids (but not systemic glucocorticoids) and bronchodilators for at least 2 months. Before treatment, subjects monitored their symptoms and peak flow values and maintained their medications for 2 weeks. At initiation, subjects inhaled either nebulized placebo (saline) or lidocaine (4%, 100 mg) 4 times daily. All subjects were instructed to reduce their inhaled glucocorticoid dosage by one half each week for 3 weeks and to discontinue glucocorticoid treatment at week 4. The subjects continued the nebulized lidocaine or placebo for a total of 8 weeks, monitored their symptoms, and used bronchodilators to control symptoms. Results: Indicators of asthma severity showed benefit for the lidocaine-treated group: changes in FEV 1 (P ≤ .001), nighttime awakenings (P ≤ .02), symptoms (P ≤ .010), bronchodilator use (P ≤ .010), and blood eosinophil counts (P ≤ .020). Subjects in both groups reduced use of inhaled glucocorticoids comparably. Subjects receiving nebulized placebo showed increases in their symptom scores, bronchodilator use (P ≤ .05 for both), and blood eosinophil counts (P ≤ .01) and decreases in FEV 1 (P ≤ .001). Conclusion: Nebulized lidocaine provided effective and safe therapy in subjects with mild-to-moderate asthma.

AB - Background: In 2 prior uncontrolled studies, nebulized lidocaine reduced oral glucocorticoid use in patients with severe glucocorticoid-dependent asthma. Objective: We tested the safety and efficacy of nebulized lidocalne in a randomized, placebo-controlled study in patients with mild-to-moderate asthma. Methods: We recruited 50 subjects (25 receiving lidocaine and 25 receiving placebo); all had a prebronchodilator FEV 1 of 64% to 125% of predicted normal value and were treated with daily inhaled glucocorticoids (but not systemic glucocorticoids) and bronchodilators for at least 2 months. Before treatment, subjects monitored their symptoms and peak flow values and maintained their medications for 2 weeks. At initiation, subjects inhaled either nebulized placebo (saline) or lidocaine (4%, 100 mg) 4 times daily. All subjects were instructed to reduce their inhaled glucocorticoid dosage by one half each week for 3 weeks and to discontinue glucocorticoid treatment at week 4. The subjects continued the nebulized lidocaine or placebo for a total of 8 weeks, monitored their symptoms, and used bronchodilators to control symptoms. Results: Indicators of asthma severity showed benefit for the lidocaine-treated group: changes in FEV 1 (P ≤ .001), nighttime awakenings (P ≤ .02), symptoms (P ≤ .010), bronchodilator use (P ≤ .010), and blood eosinophil counts (P ≤ .020). Subjects in both groups reduced use of inhaled glucocorticoids comparably. Subjects receiving nebulized placebo showed increases in their symptom scores, bronchodilator use (P ≤ .05 for both), and blood eosinophil counts (P ≤ .01) and decreases in FEV 1 (P ≤ .001). Conclusion: Nebulized lidocaine provided effective and safe therapy in subjects with mild-to-moderate asthma.

KW - Asthma

KW - Eosinophils

KW - Glucocorticoids

KW - Lidocaine

UR - http://www.scopus.com/inward/record.url?scp=2342476447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342476447&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2004.02.039

DO - 10.1016/j.jaci.2004.02.039

M3 - Article

C2 - 15131566

AN - SCOPUS:2342476447

VL - 113

SP - 853

EP - 859

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5

ER -